glp-1 microdosing vs full dose Microdosing: Risks, Benefits and What to Know Before Changing Your GLP-1 medications are changing how

GLP-1 drugs have been linked to several eye problems, including: Non-arteritic anterior ischemic optic neuropathy (NAION) Optic neuropathy Retinal ischemia Exacerbation of diabetic retinopathy These GLP-1 eye problems can range from mild visual field defects to complete blindness in one eye

No big RCTs evaluate BPC-157 for fertility outcomes, such as conception, live birth, or enhanced ovarian reserve

Herbs like oregano, clove, eucalyptus, rosemary, cinnamon, ginger, and curcumin are all-natural biofilm disruptors

Losing weight can change your face

These observations led to an interesting development bifurcation : Melanotan I (Afamelanotide) continued as a skin peptide and in 2014 received approval as Scenesse for erythropoietic protoporphyria (a rare genetic disease with severe photosensitivity) Melanotan II was abandoned as a cutaneous drug PT-141 / Bremelanotide , a fragment of Melanotan II targeted at MC4R, was developed as a sexual stimulant and in 2019 approved as Vyleesi for hypoactive sexual desire disorder in women (HSDD) Second life in research and the cosmetic underground Melanotan II never reached commercial approval as a drug, but in the research community and cosmetic underground it became well known